Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
The role of tumour marker testing in early diagnosis

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 811

Dr Craig Barrington - South West Wales Cancer Centre, UK

Dr Barrington speaks with ecancer at ESMO 2017 about perspectives from his local tumour board, where he describes a large number of repeated tumour marker tests conduct resulting in little clinical significance.

He describes the economic benefit of testing requests being made in adherence to NICE guidelines, and questions how appropriate repeated testing is considering the delay in care and risk to patient well-being, when no clinically actionable information may be available.

Dr Barrington encourages appropriate use of tumour marker screening where available, and that cost and benefit be considered more closely.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence